This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-05. Anything still debated is marked as such rather than presented as settled.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
In music, birdsong has influenced composers and musicians in several ways: they can be inspired by birdsong; they can intentionally imitate bird song in a composition, as Vivaldi, Messiaen, and Beethoven did, along with many later composers; they can incorporate recordings of birds into their works, as Ottorino Respighi first did; or like Beatrice Harrison and David Rothenberg, they can duet with birds. A 2023 archaeological excavation of a 10,000-year-old site in Israel yielded hollow wing bones of coots and ducks with perforations made on the side that are thought to have allowed them to be used as flutes or whistles possibly used by Natufian people to lure birds of prey.
=== Protein-based materials and sustainability === A major strand of Mezzenga's work concerns the development of protein-derived and food-based materials as sustainable platforms for advanced technologies. His group has pioneered the use of amyloid fibrils as building blocks for functional nanocomposites, including biodegradable materials with sensing and shape-memory properties. In 2016, Mezzenga and collaborators reported amyloid–carbon hybrid membranes for universal water purification. The technology exploits supramolecular metal–ligand interactions between heavy-metal ions and protein amyloid fibrils, allowing simultaneous removal of a wide range of contaminants with high binding affinities. The membranes exhibit unusually high permeability, enabling operation with minimal energy input. This research led to patented technologies and the creation of an ETH Zurich spin-off company, BluAct Technologies, which has tested and deployed the approach in multiple countries. Mezzenga has also contributed to the development of conceptual frameworks for evaluating the sustainability of water purification technologies at large, emphasizing energy efficiency and material performance.
Creatine-alpha-ketoglutarate is a salt formed from alpha-ketoglutaric acid (AKG) and creatine. Creatine is a mass-produced fitness supplement that is supposed to increase the user's muscle mass, strength and power. Creatine requires a delivery system for cell uptake. An example is arginine alpha-ketoglutarate. Arginine alpha-ketoglutarate itself is a chemical compound that is supposed to increase the blood flow to muscles and therefore, increase nutrient delivery to muscle cells. Alpha-ketoglutarate (α-KG or AKG) itself is a central molecule in the Krebs cycle that controls the organism's overall citric acid cycle rate. It can improve bone tissue development in the skeletal muscles by decreasing protein catabolism and increasing protein synthesis. The supplement industry has theorized that binding creatine to alpha-ketoglutarate could show significant improvements in creatine delivery and uptake which would ultimately lead to greater improvements in muscle mass and performance. Still relatively new in the fitness industry, more research is needed to test the validity of its effects.
Sources: en.wikipedia.org
By the mid-1980s, over 65 papers on the topic of coupling reactions involving tin had been published, continuing to explore the substrate scope of this reaction. While initial research in the field focused on the coupling of alkyl groups, most future work involved the much more synthetically useful coupling of vinyl, alkenyl, aryl, and allyl organostannanes to halides. Due to these organotin reagent's stability to air and their ease of synthesis, the Stille reaction became common in organic synthesis.
During the 2014 GPU Technology Conference, Nvidia announced a port of Portal to the Nvidia Shield. The port was released on May 12, 2014. Alongside Portal 2, Portal was released on the Nintendo Switch on June 28, 2022, as part of the Portal: Companion Collection, developed by Valve and Nvidia Lightspeed Studios. Portal with RTX was announced by Nvidia during its GeForce Beyond event in September 2022. A remaster of the original, the game is intended to demonstrate the functionality of the GeForce 40 series graphics cards with real-time path tracing. Initially planned for release in November 2022, it was ultimately released December 8, 2022, as a free DLC.
To determine the pore diameter, physical methods such as porosimeter (mercury, liquid-liquid porosimeter and Bubble Point Test) are also used, but a certain form of the pores (such as cylindrical or concatenated spherical holes) is assumed. Such methods are used for membranes whose pore geometry does not match the ideal, and we get "nominal" pore diameter, which characterizes the membrane, but does not necessarily reflect its actual filtration behavior and selectivity. The selectivity is highly dependent on the separation process, the composition of the membrane and its electrochemical properties in addition to the pore size. With high selectivity, isotopes can be enriched (uranium enrichment) in nuclear engineering or industrial gases like nitrogen can be recovered (gas separation). Ideally, even racemics can be enriched with a suitable membrane. When choosing membranes selectivity has priority over a high permeability, as low flows can easily be offset by increasing the filter surface with a modular structure. In gas phase filtration different deposition mechanisms are operative, so that particles having sizes below the pore size of the membrane can be retained as well.
=== Agents of spontaneous missense mutation === Environmental mutagens, such as tobacco smoke or UV radiation, may be a cause of spontaneous missense mutations. Tobacco smoke has been implicated in transversion mutations in the K-ras gene, with a meta-analysis of lung carcinomas showing 25 tumours containing a G to T mutation causing an amino acid change from glycine to cysteine, and 11 tumours with a G to T mutation causing an amino acid change from glycine to valine. Similarly, numerous studies have shown ultraviolet light induces missense mutations in the p53 gene, which when unregulated, reduces the cell's ability to recognize DNA damage and engage in apoptosis, leading to cell proliferation and potential skin carcinogenesis.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.